Beta-blockers for the treatment of cardiovascular disease in COPD patients

Author

Veshudha Kang, University of the PacificFollow

Date of Award

4-1-2020

Document Type

Capstone

Degree Name

Master of Physician Assistant Studies

Department

Physician Assistant Education

First Advisor

Rahnea Sunseri

Abstract

Patients with chronic obstructive pulmonary disease (COPD) have high rates of cardiovascular comorbidities, including hypertension, ischemic heart disease, and heart failure. These comorbidities further complicate management of COPD patients. Cardiovascular complications are especially difficult to manage during acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Multiple factors are contributory, including hypoxemia, tachycardia, increased inflammation, and arterial stiffness. Cardioselective beta-blockers have been proven to be safe and effective in managing cardiovascular conditions such as heart failure and arrhythmias and are recommended for acutely decompensated heart failure and myocardial infarction in the setting of AECOPD. Benefits include reducing all-cause mortality and the risk of COPD exacerbations.1 However, beta-blockers continue to be underused in COPD patients due to lingering concerns about bronchospasm leading to exacerbation of COPD symptoms requiring hospitalization. Whether the use of beta-blockers for cardiovascular disease in patients with COPD would decrease pulmonary function or increase frequency of exacerbations, hospitalizations, and mortality will be examined.

Recommended Citation

Kang, Veshudha, "Beta-blockers for the treatment of cardiovascular disease in COPD patients" (2020). Physician Assistant Capstones. 63.
https://scholarlycommons.pacific.edu/pa-capstones/63